Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk wins European approval for Refixia

Plans to launch the haemophilia B treatment in the fourth quarter

Novo Nordisk

Novo Nordisk has won EU approval for its new haemophilia drug Reflixia and is planning its first European launches in the fourth quarter.

The European Commission marketing authorisation comes one week after US regulators gave the green light to the drug, which is a long-acting Factor IX treatment for haemophilia B.

Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk, said: "We are excited about the approval of Refixia in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia B.

"The strong clinical profile of Refixia provides haemophilia B patients with better protection against bleeds, even into damaged joints, and an overall improved quality of life."

The half-life of Refixia (nonacog beta pegol or N9-GP) is around five times longer

than standard factor IX products, meaning fewer injections are needed,

Consequently Novo is hoping the new product will help defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog alfa) from Biogen and Swedish Orphan Biovitrum which was approved in the EU last year.

Article by
Dominic Tyer

7th June 2017

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

women
Advancing women in healthcare
Fostering the next generation of leaders...
The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...

Infographics